Allurion Technologies (NYSE:ALUR – Get Free Report) and GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares Allurion Technologies and GE HealthCare Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allurion Technologies | -199.96% | N/A | -77.13% |
| GE HealthCare Technologies | 10.11% | 21.35% | 5.91% |
Valuation & Earnings
This table compares Allurion Technologies and GE HealthCare Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allurion Technologies | $17.21 million | 0.59 | -$7.20 million | ($10.56) | -0.08 |
| GE HealthCare Technologies | $20.63 billion | 1.62 | $2.08 billion | $4.56 | 16.05 |
GE HealthCare Technologies has higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Allurion Technologies has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Allurion Technologies and GE HealthCare Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allurion Technologies | 1 | 1 | 1 | 0 | 2.00 |
| GE HealthCare Technologies | 1 | 6 | 7 | 0 | 2.43 |
Allurion Technologies currently has a consensus target price of $3.00, suggesting a potential upside of 261.27%. GE HealthCare Technologies has a consensus target price of $90.75, suggesting a potential upside of 24.01%. Given Allurion Technologies’ higher probable upside, equities analysts plainly believe Allurion Technologies is more favorable than GE HealthCare Technologies.
Institutional and Insider Ownership
21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
GE HealthCare Technologies beats Allurion Technologies on 12 of the 14 factors compared between the two stocks.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
About GE HealthCare Technologies
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
